ESPE Abstracts

ESPE Abstracts

Published by BioScientifica
Previous issue | Volume 97 | ESPE2023 | Next issue

61st Annual ESPE (ESPE 2023)

The Hague, Netherlands
21 Sept 2023 - 23 Sept 2023

Card image cap
The 61st ESPE Annual Meeting will now be taking place in The Hague, The Netherlands

Poster Category 1

GH and IGFs

Previous section
Fetal, Neonatal Endocrinology and Metabolism
Table of contents
Next section
Growth and Syndromes

hrp0097p1-95 | GH and IGFs

Clinical and laboratory characteristics in children with growth hormone deficiency (GHD) and short stature unresponsive to stimulation tests (SUS)

hrp0097p1-96 | GH and IGFs

Modified Insulin Stress Test for Assessment of Growth Hormone Secretion – Experience from a University Teaching Hospital

hrp0097p1-97 | GH and IGFs

Efficacy of long-acting growth hormone preparation in children with growth hormone deficiency

hrp0097p1-98 | GH and IGFs

Evaluation of patients with growth hormone deficiency during the transition period

hrp0097p1-99 | GH and IGFs

Clinicians’ perceptions on ease of use and usefulness of Aluetta® Smartdot™ and comprehensive digital health ecosystem in Italy to support patients receiving r-hGH treatment

hrp0097p1-100 | GH and IGFs

Exploring healthcare professionals’ attitudes towards digitalization and the perceived usefulness and ease of use of digital solutions in patients receiving growth hormone therapy: Results of a Korean participatory study

hrp0097p1-101 | GH and IGFs

Withdrawing growth hormone treatment at mid-puberty in idiopathic isolated growth hormone deficiency: baseline characteristics in patient-preference design study

hrp0097p1-102 | GH and IGFs

Assessment of clinical pediatric perception of short stature in childhood and challenges to treat with Growth Hormone in Brazil: A exploratory evaluation of a developing country daily practice.

hrp0097p1-103 | GH and IGFs

Assessing the treatment burden and Quality of Life of children receiving daily recombinant Growth Hormone treatment in Greece

hrp0097p1-104 | GH and IGFs

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a French participatory study

hrp0097p1-105 | GH and IGFs

Effects of Growth Hormone Therapy on Glucose Metabolism in Children and Adolescents: 1-year follow-up results

hrp0097p1-106 | GH and IGFs

Growth Hormone (GH) Therapy in Children with short stature: A cross-sectional study of indication and treatment outcomes- 12-year single center experience

hrp0097p1-107 | GH and IGFs

The Growth Predictive Value of (IGF1/Growth Hormone Peak) Ratio in Children with Idiopathic Short Stature (ISS)

hrp0097p1-108 | GH and IGFs

A challenging case of Pituitary Gigantism

hrp0097p1-288 | GH and IGFs

The Growzen™ buddy smartphone application shows positive findings on adherence in Argentinian patients receiving growth hormone therapy for growth disorders

hrp0097p1-289 | GH and IGFs

Long-term effectiveness and safety of growth hormone therapy in Japanese children with short stature due to Noonan syndrome (NS): real-world data

hrp0097p1-290 | GH and IGFs

Optimal injection device settings to achieve high adherence to growth hormone treatment in patients with growth disorders

hrp0097p1-291 | GH and IGFs

Adult heights of the cases whose GH treatment was discontinued at early retesting reached their target heights

hrp0097p1-292 | GH and IGFs

Clinical predictors of good/poor response to growth hormone treatment (GHT) in children with idiopathic short stature (ISS)

hrp0097p1-293 | GH and IGFs

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a UK participatory study

hrp0097p1-294 | GH and IGFs

A novel variant of IGF1R in a Chinese family with short stature and efficacy of recombinant human growth hormone therapy

hrp0097p1-295 | GH and IGFs

Sex steroid priming decreases the frequency of divergent results between spontaneous and stimulated GH tests

hrp0097p1-296 | GH and IGFs

The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys

hrp0097p1-297 | GH and IGFs

Evening or morning growth hormone treatment?

hrp0097p1-298 | GH and IGFs

Quality of life at adult height in adolescents and young adults treated by GH

hrp0097p1-299 | GH and IGFs

Real-world adherence to growth hormone treatment and catch-up growth in children with growth disorders in France: An interim analysis from the SCOPE study

hrp0097p1-300 | GH and IGFs

Assessment of the rhGH treatment compliance in children with growth hormone deficiency.

hrp0097p1-301 | GH and IGFs

Outcome of growth hormone treatment in growth hormone deficient children over the course of 3 years in Notre Dames Des Secours-University Medical Center Byblos-Lebanon-single center experience

hrp0097p1-302 | GH and IGFs

Influencing Factors on Selection of Initial Treatment Dose in Children Diagnosed with Isolated Growth Hormone Deficiency

hrp0097p1-303 | GH and IGFs

Further analyses on the role of IGF-I in the diagnosis of GH deficiency (GHD) in children

hrp0097p1-304 | GH and IGFs

Prevalence and predictors for growth hormone deficiency in children born small for gestational age with short stature

hrp0097p1-305 | GH and IGFs

A rare case of microduplication 5q35.2-q35.3, also known as anti-Sotos syndrome, in a female patient.

hrp0097p1-489 | GH and IGFs

Effects of GH therapy in patients with GHD (Growth Hormone Deficiency) on glucose homeostasis: results of a 10-years follow-up

hrp0097p1-490 | GH and IGFs

Phenotype and genotype of children with biallelic GHRHR gene mutations: a Belgian case series

hrp0097p1-491 | GH and IGFs

Priming with sex steroids increases the specificity of GH tests in the diagnosis of “True” isolated growth hormone deficiency

hrp0097p1-492 | GH and IGFs

GH stimulation testing: is it time to change the paradigm?

hrp0097p1-493 | GH and IGFs

Use of aromatase inhibitors in short children and adolescents to optimize final height: A current practice survey

hrp0097p1-494 | GH and IGFs

Comparison of insulin tolerance test and arginine test in the diagnosis of growth hormone deficiency in children

hrp0097p1-495 | GH and IGFs

Difficulties in interpreting insulin-like growth factor 1 (IGF-1) levels in short stature children born small for gestational age (SGA) treated with recombinant human growth hormone (rhGH) based on data from six clinical centres in Poland.

hrp0097p1-496 | GH and IGFs

Comparative Efficacy of Growth Hormone treatment on children with Idiopathic Growth Hormone Deficiency (and Idiopathic Short Stature (A 12year Tertiary Center Experience

hrp0097p1-497 | GH and IGFs

First-year response to growth hormone (rGH) treatment and assessment of iGRO software for the prediction of growth velocity.

hrp0097p1-498 | GH and IGFs

The relationship between body mass index and therapeutic effect in children with idiopathic growth hormone deficiency

hrp0097p1-499 | GH and IGFs

Growth characteristics and final height in survivors of childhood medulloblastoma.

hrp0097p1-500 | GH and IGFs

Factors influencing response to growth hormone therapy in patients with growth hormone deficiency

hrp0097p1-501 | GH and IGFs

The Predictive Value of using IGF1/Growth Hormone Peak Ratio on growth parameters in Children with Growth Hormone Deficiency (GHD) before and after GH treatment.

hrp0097p1-502 | GH and IGFs

Integration of Nurse-Led Virtual Reviews with Growth Hormone Device-Linked Adherence: a mixed methods, feasibility study

hrp0097p1-503 | GH and IGFs

Risk factors and best predictor of Osteopenia in preterm Neonates: single center experience

hrp0097p1-504 | GH and IGFs

The pattern of growth in a girl with short stature and duplication at 5q35.2q35.3 encompassing NSD1

Published by BioScientifica

ESPE Abstracts

© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more